Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo

NCT06694740 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT06694740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06694740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Phase 2/3
Overall status
Recruiting
Start date
February 24, 2026
Completion date
May 31, 2029
Enrollment
170 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adult patients admitted to intensive care with initial severity (sofa of the first 24 hours post-admission ≥ 6, adult under mechanical ventilation, and presenting an mhla-dr less than 8,000ab/c, post-aggressive immunosuppression